Roche Holding AG (SWX: RO)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 226.64B |
| Revenue (ttm) | 60.58B |
| Net Income (ttm) | 10.62B |
| Shares Out | n/a |
| EPS (ttm) | 13.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Mar 14, 2024 |
| Volume | 28,206 |
| Open | 302.00 |
| Previous Close | 302.80 |
| Day's Range | 299.60 - 303.20 |
| 52-Week Range | 229.40 - 312.00 |
| Beta | 0.15 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 18, 2024 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, d... [Read more]
Financial Performance
In 2023, RO's revenue was 60.44 billion, a decrease of -8.16% compared to the previous year's 65.81 billion. Earnings were 11.50 billion, a decrease of -7.43%.
Financial StatementsNews
Roche's fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis
Basel, 04 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new 48-week data for the investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib from the Phase II FENopta open...
Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles
Friday, Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) stock is trading lower after the company shared detailed results from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardiomyop...
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.
U.S. economy is 'amazingly strong,' David Roche says
David Roche, president of Quantum Strategy, discusses the state of the U.S. economy and outlook for Federal Reserve interest rates.
Roche's PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH
Basel, 27 August 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved PiaSky® (crovalimab), a novel recycling monoclonal antibody that inhibits the compl...
Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain
Labcorp Holdings Inc (NYSE: LH) is reportedly collaborating with U.S. health regulators to determine whether it should scale up its mpox testing capabilities, following global concerns over a newly d...
Mpox outbreak: Roche working to enhance lab testing capacity to combat virus
Roche says it is working to enhance lab testing capacity for mpox worldwide
Roche is actively working to enhance laboratory testing capacity for mpox worldwide, the Swiss pharmaceutical company said on Tuesday.
Roche responds to WHO's declaration of a global health emergency due to the ongoing mpox outbreak
Basel, 20 August 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it is supporting the international response to the mpox global health emergency with its diagnostic tests developed for ...
Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings
In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comp...
Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years
Should Novo Nordisk and Eli Lilly investors be worried about Roche?
J&J, Roche come out on top in S&P ratings of strongest pharma companies
Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market
Roche Holding AG (OTC: RHHBY) reportedly turned down a potential blockbuster weight-loss pill in 2018, allowing Eli Lilly And Co (NYSE: LLY) to acquire the drug, now known as orforglipron, for just ...
Roche: A Long-Term Bottom May Have Been Struck (Technical Analysis)
Bear Market 'Is Probably Coming' In 2025, Veteran Investor Warns Of AI Bubble And Fed's Insufficient Rate Cuts Amid Sluggish Economy
David Roche , a seasoned investor, has warned of an impending bear market in 2025, citing reasons such as a sluggish U.S. economy, an artificial intelligence bubble, and insufficient rate cuts. What H...
Bear market is probably coming in 2025, veteran investor David Roche says
David Roche, strategist at Quantum Strategy, discusses the two factors that will cause it.
Merck Stops Lung Cancer Study For Keytruda Combo Due To Ineffective Results, Side Effects
On Thursday, Merck & Co Inc (NYSE: MRK) announced discontinuing the Phase 3 KeyVibe-008 trial based on an independent Data Monitoring Committee (DMC) recommendation . The trial is evaluating the inve...
Roche Considers Selling Cancer Data Specialist Flatiron Health Business, Highlights Challenges With Start-Up Acquisitions
Roche Holding AG (OTC: RHHBY) is reportedly contemplating the divestiture of Flatiron Health , a cancer data specialist Roche acquired in 2018 for $1.9 billion. The move underscores the complexities ...
Roche evaluating selling cancer startup Flatiron Health
Roche considering divesting $1.9 bln cancer data startup, FT reports
Swiss pharmaceutical company Roche is considering divesting cancer data specialist Flatiron Health, the Financial Times reported on Wednesday, citing people familiar with the matter.
Roche, Sangamo ink licensing deal for neuro drugs
European Commission approves Roche's Vabysmo for treatment of retinal vein occlusion (RVO)
Basel, 30 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved Vabysmo® (faricimab) for the treatment of visual impairment due to macular edema...
Roche ‘fast-tracking' weight-loss drug that rivals Wegovy
Pharmaceutical giant Roche is "fast-tracking" its own weight-loss pills in clinical trials as it looks to compete with Novo Nordisk's Wegovy and Eli Lilly's Zepbound.
Swiss pharma giant Roche to accelerate Wegovy rival drugs after positive trial data
Swiss pharmaceutical giant Roche said Monday it is accelerating the development of its Wegovy rival weight loss drugs following promising early stage trial data. The company's two obesity drug candida...
Roche closes acquisition of LumiraDx's Point of Care technology to expand access to diagnostic testing in primary care
Basel, 29 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the completion of the acquisition of LumiraDx's Point of Care technology, following the receipt of all required antitrust and r...